Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
38 hedge funds and large institutions have $11.2M invested in Oncternal Therapeutics, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 38 → 38 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
34% less call options, than puts
Call options by funds: $19K | Put options by funds: $29K
47% less capital invested
Capital invested by funds: $21M → $11.2M (-$9.88M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$177K |
| 2 |
FHA
First Horizon Advisors
Memphis,
Tennessee
|
+$133K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$97.9K |
| 4 |
SIM
Spark Investment Management
New York
|
+$64.3K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$39.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$66K |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$39.5K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$28K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$16.1K |
| 5 |
OC
Oppenheimer & Co
New York
|
-$16K |
ONCT Hedge Fund Activity: Q3 2015 in Review
38 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2015, worth a combined $11.2M — down 47% from $21M a quarter earlier.
Fund positioning in ONCT was balanced in Q3 2015: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 9 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $177K. The largest seller was Rotella Capital Management, exiting entirely with an estimated $66K sold.
- 38 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $11.2M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2015, down 47% quarter-over-quarter.
- 5 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2015 and 5 closed out, a net change of 0 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2015 was Geode Capital Management, an estimated $177K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2015 was Rotella Capital Management, an estimated $66K sold.
Based on aggregated 13F filings for Q3 2015.